Are We Prepared for the CDK4/6 Revolution With HR+/HER2- Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
Breast Cancer (Auckl)
.
2023 Nov 28:17:11782234231215192.
doi: 10.1177/11782234231215192.
eCollection 2023.
Authors
Seyla Azoz
1
,
Martin Peters
2
,
Graham Jones
1
3
Affiliations
1
Customer Experience and Engagement, Novartis Pharmaceuticals, Cambridge, MA, USA.
2
Customer Experience and Engagement, Novartis Pharma AG, Basel, Switzerland.
3
Clinical and Translational Science Institute, Tufts University Medical Center, Boston, MA, USA.
PMID:
38034323
PMCID:
PMC10685741
DOI:
10.1177/11782234231215192
No abstract available